Log in
  • Home
  • News
  • FDA accepted a New Drug Application (NDA) for MDMA

FDA accepted a New Drug Application (NDA) for MDMA

03/13/2024 11:57 AM | Anonymous member (Administrator)

The FDA has accepted a New Drug Application (NDA) for midomafetamine capsules (MDMA) intended for use in combination with psychological intervention and other supportive services for individuals with PTSD. If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy available. Read more here.


On February 8, 2024, the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) held a hearing with CEOs from J&J, Merck, and BMS regarding the high cost of prescription drugs in the U.S. While the CEOs offered policy recommendations to help reduce costs, they could not commit to reducing prices to levels comparable with list prices in other countries. Read more here.

About CSHP

Since 1948, the Connecticut Society of Health-System Pharmacists has represented the professional interests and provided professional development for CT pharmacists, educators and pharmacists in training.


c/o Impact Association Management 

1502 W Broadway, Suite 102, Madison, WI 53713

Email: office@cshponline.org

Phone: 203-489-9861

Copyright © Connecticut Society of Health-System Pharmacists
Powered by Wild Apricot Membership Software